clinical diagnostics research News
-
Creative Enzymes Upgrades Multiple Diagnostic Enzyme Products for Clinical and Diagnostic Research
Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained solid reputation. Recently, Creative Enzymes has announced multiple ...
-
Kephera Diagnostics’ new CLIA laboratory launches testing for COVID-19 antibodies
Kephera Diagnostics announced today that it has been approved as a CLIA certified laboratory by the Massachusetts Dept of Public Health and the U.S. Centers for Medicare and Medicaid, and is now offering COVID-19 antibody testing in Massachusetts and 44 other states. Kephera will use an ELISA (Enzyme-Linked Immunosorbent Assay) test that it developed in-house, which is based on the ...
-
DNAnexus to Showcase Platform Scalability, Versatility, and Security at ASHG 2022 Annual Meeting
DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced the speaker lineup for its customer presentations at the American Society of Human Genetics (ASHG) 2022 Annual Meeting, which is being held in Los Angeles this week. The company will also be showcasing its GxP-compliant platform and new Nextflow pipeline language ...
-
Kephera Diagnostics receives Phase II contract from the National Cancer Institute for a test for liver fluke, an exotic parasite linked to bile duct cancer
Kephera Diagnostics has been awarded a $1,999,961 million Phase II Small Business Innovative Research (SBIR) contract by the National Cancer Institute, an agency of the National Institutes of Health, for a test for liver fluke infection, the Company announced today. Kephera had previously received a $300,000 Phase I contract to develop and demonstrate the feasibility of its test. Liver flukes ...
-
Kephera Diagnostics launches CLIA test for quantitative antibody response to COVID-19 vaccination
Kephera Diagnostics announced today the launch of a quantitative test to measure the level of antibodies elicited by vaccination against COVID-19, as well as by COVID-19 infection. The test will be available as a service through Kephera’s CLIA-certified laboratory. Kephera’s COVI-QUANT™ test measures the level of IgG antibodies to the spike protein, a viral component which is ...
-
Bruker Appoints Robert Rosenthal to Board of Directors
Bruker Corporation (NASDAQ:BRKR) today announced that it has appointed Dr. Robert Rosenthal to its Board of Directors, effective immediately. Dr. Rosenthal currently serves as Chief Executive Officer and as a director for Taconic Biosciences, Inc., a privately-held provider of research models for the pharmaceutical and biotech industry, a position he has held since joining Taconic Biosciences in ...
-
Bio-Techne Announces Paper Publication in Annals of Oncology
This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid biopsies such as cfDNA and CTC analysis. The exosome field has gone through a rapid growth phase in parallel with the increasing attention over the potential of liquid biopsies. Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne ...
-
NIAID awards Phase I contract to Kephera Diagnostics for the development of a new test for Chagas disease
The National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH), has awarded a Phase I, $300,000 Small Business Innovative Research (SBIR) contract to Kephera Diagnostics to develop a new test for Chagas disease, the company announced today. The contract, awarded in response to a targeted solicitation from NIAID aimed at improving ...
-
CD Genomics Unveils Cutting-edge DAP-Seq Service Revealing the Hidden Secrets of DNA
CD Genomics, a global leader in genomics solutions, has recently unveiled its highly anticipated DAP-Seq service. This cutting-edge offering promises to provide researchers worldwide with an efficient application solution for DNA affinity purification sequencing technology. With this service, the company aims to revolutionize the field of life sciences and empower researchers to unlock the ...
By CD Genomics
-
CD Genomics Launches Advanced Whole Exome Sequencing Service, Empowering Genetic Research
CD Genomics, a renowned provider of genomics services, is proud to unveil its cutting-edge Whole Exome Sequencing (WES) service. This offering provides researchers and clinicians with a powerful tool to investigate the exome, shedding light on the intricacies of the human genome and propelling our understanding of genetic diseases. In the era of precision medicine, comprehensive and precise ...
By CD Genomics
-
Optina Diagnostics announces a collaborative clinical research study with the Alzheimer Center Amsterdam, Amsterdam UMC
Optina Diagnostics announces today that it has signed an agreement with the Alzheimer Center Amsterdam, part of the Amsterdam University Medical Center to pursue the study of Optina’s Retinal Deep Phenotyping Platform™? in a cohort of 100 subjects. July 29, 2020 Optina Diagnostics announces today that it has signed an agreement with the Alzheimer Center Amsterdam, part of the ...
-
CD Genomics RNA-Solutions Platform Now Provides Whole Transcriptome Sequencing Service
RNA-Solutions is a platform for revolutionary research in RNA, targeting coding and non-coding RNAs with different physiological functions. Scientists at CD Genomics are ready to help detect various types of RNAs via meticulous and integrative approaches. Powered by the Illumina, Pacbio SMRT, and Nanopore sequencing platforms, CD Genomics offers services performed by de novo and reference-based ...
By CD Genomics
-
Untargeted Lipidomics Now Available with Creative Proteomics’s New Cutting-Edge Lipidomics Platform
As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnology companies, and pharmaceutical companies. The company has recently announced the fully-developed untargeted lipidomics service, which can analyze hundreds of different lipids simultaneously, and is widely used ...
-
CD Genomics RNA Diversifies Its RNA Service Portfolio by Adding Whole Transcriptome Sequencing
RNA Solutions is the platform that offers services on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The scientists at CD Genomics are ready to help detect various types of RNA via meticulous and integrative approaches. To further enrich its service types, the company recently announced to add Whole Transcriptome Sequencing to its ...
By CD Genomics
-
Hummingbird Diagnostics Publishes Study of miRisk as a Predictor of Immunotherapy Efficacy in Advanced-Stage NSCLC
Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research Reports Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic ...
-
Canadian Government-Sponsored Collaboration Targets Standardized Cancer Testing
Genome Canada, the Ontario Institute for Cancer Research (OICR) and Thermo Fisher Scientific are collaborating to develop a complete solution of targeted next generation sequencing (NGS) assays and analysis software designed to more effectively assess – and eventually improve management of – pancreatic, prostate and breast cancer. The $6 million, three-year initiative aims to ...
-
PixCell Medical Partners with Axonlab to Distribute Point-of-Care Hematological Analyzer HemoScreen Across Europe
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, today announced an exclusive distribution agreement with Axonlab, a leader in point-of-care testing in Europe providing the healthcare sector with equipment and services in the fields of medical diagnostics, life science, and software solutions, to distribute the HemoScreen™, PixCell's hematology analyzer, in key ...
-
C2N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology
On World Alzheimer’s Day, Missouri leaders and economic development officials praise C2N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease. C2N Diagnostics has expanded its lab facilities to 13,320 square feet in the Cortex ...
-
Alzheimer’s Breakthrough: C2N First to Offer a Widely Accessible Blood Test
Who Want Earlier Answers Patients, advocates, and physicians who have long awaited an easy to administer blood test that can help them better understand Alzheimer’s disease now have a health care innovation which they can rely upon. A breakthrough in Alzheimer’s disease has arrived with the introduction of C2N Diagnostics’ PrecivityAD™ blood test into the clinic. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you